Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials

Annals of Thoracic Surgery

Volumn 70, Issue 2, 2000, Pages 516-526

  Lincoff, A Michael ^a,b,c,d,e   Lenarz, Leroy A ^a,b,c,d,e   Despotis, George J ^a,b,c,d,e   Smith, Peter K ^a,b,c,d,e   Booth, Joan E ^a,b,c,d,e   Raymond, Russell E ^a,b,c,d,e   Sapp, Shelly K ^a,b,c,d,e   Cabot, Catherine F ^a,b,c,d,e   Tcheng, James E ^{a,b,c,d,e,n,ce}   Califf, Robert M ^a,b,c,d,e   Effron, Mark B ^a,b,c,d,e   Topol, Eric J ^a,b,c,d,e   Kereiakes, Dean J ^f   Runyon, John Paul ^f,cg   Kelly, Thomas ^g   Timmis, George ^h   Kleiman, Neal S ^i,bq   Kramer, Jeffrey ^j,bo   Talley, David ^k   Navetta, Frank I ^l   Kraft, Phillip ^m   Ferguson, James ^o   Browne, Kevin ^p,bx   Blankenship, James ^q   Ivanhoe, Russell ^r   Shadoff, Neal ^s   Taylor, Mark ^t   Gacioch, Gerald ^u   Bates, Eric ^v,cc   Snyder, H A ^w   Bass, Theodore A ^x   Bear, Philip ^y   Hattel, Larry ^z   Anderson, H Vernon ^aa,ci   Hettleman, Bruce ^ab   Teirstein, Paul S ^ac   Sarembock, Ian ^ad,bw   Davidson, Charles J ^ae   Aguirre, Frank V ^af   Azrin, Michael ^ag,ak   Worley, Seth ^ah,bc,bz   Marquis, Jean Francois ^ai   Spriggs, Douglas J ^aj   Weston, Mark W ^al   George, Barry S ^am   Ricci, Donald R ^an,bt   Hartman, Carl W ^ao   Farah, Anthony ^ap   Sander, Gary ^aq   Reen, Bernard M ^ar   Heuser, Richard ^as   Larkin, Timothy ^at   Popma, Jeffrey ^au   Sanz, Mark L ^av,ch   Burton, Jeffrey ^aw   Brown, Robert I G ^ax   French, William J ^ay   Adelman, Allan G ^az,bp   Gottlieb, Ronald ^ba   King, Spencer B ^bb   Ducas, John ^bd,bn   Hochman, Judith S ^be   O'Neill, Blair J ^bf   Cheung, Po Kee ^bg   Knudtson, Merril ^bh   Samaha, Joseph ^bi   Klein, Lloyd W ^bj   Almond, David ^bk   Rosenberg, Michael J ^bl   Unks, Michael ^bm   Cohen, Eric ^br   Webb, John C ^bs   Tanguay, Jean Francois ^bu   Coleman, Patrick S ^bv   Thompson, Mark ^u   Gradman, Alan ^by   Yakubov, Steven ^ca   Tannenbaum, Mark ^cb   Gonzalez, Mark ^cd   Bach, Richard ^af   Cummins, Frank E ^cf   Lucore, Charles ^cj   Muhlestein, Brent ^ck   Chisholm, Robert ^cl   Del Core, Michael ^cm   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e CENTOCOR INC   (United States)

^f UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^g MOSES H CONE MEMORIAL HOSPITAL   (United States)

^h WILLIAM BEAUMONT HOSPITAL   (United States)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^j Our Lady of Lourdes Medical School   (United States)

^k UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

^l Mother Frances Hospital   (United States)

^m HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

ⁿ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^o TEXAS HEART INSTITUTE   (United States)

^p LAKELAND REGIONAL MEDICAL CENTER   (United States)

^q GEISINGER MEDICAL CENTER   (United States)

^r FLORIDA HOSPITAL   (United States)

^s Presbyterian Hospital Albuquerque   (United States)

^t DEBORAH HEART AND LUNG CENTER   (United States)

^u ROCHESTER GENERAL HOSPITAL   (United States)

^v UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^w Department of Anesthesiology   (United States)

^x UNIVERSITY OF FLORIDA HEALTH JACKSONVILLE   (United States)

^y Iowa Methodist Hospital   (United States)

^z Cheyenne Regional Medical Center   (United States)

^aa MEMORIAL HERMANN HOSPITAL   (United States)

^ab DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^ac SCRIPPS RESEARCH INSTITUTE   (United States)

^ad UNIVERSITY OF VIRGINIA   (United States)

^ae NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^af SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

^ag UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^ah LANCASTER GENERAL HOSPITAL   (United States)

^ai UNIVERSITY OF OTTAWA   (Canada)

^aj Morton Plant Hospital   (United States)

^ak HARTFORD HOSPITAL   (United States)

^al TAMPA GENERAL HOSPITAL   (United States)

^am RIVERSIDE METHODIST HOSPITAL   (United States)

^an VANCOUVER GENERAL HOSPITAL   (Canada)

^ao SENTARA NORFOLK GENERAL HOSPITAL   (United States)

^ap ALLEGHENY GENERAL HOSPITAL   (United States)

^aq LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^ar PRESBYTERIAN HOSPITAL   (United States)

^as ARIZONA HEART INSTITUTE   (United States)

^at EVANSTON HOSPITAL   (United States)

^au WASHINGTON HOSPITAL CENTER   (United States)

^av St Patrick Hospital and Health Sciences Center   (United States)

^aw UNIVERSITY OF ALBERTA   (Canada)

^ax ROYAL COLUMBIAN HOSPITAL   (Canada)

^ay HARBOR UCLA MEDICAL CENTER   (United States)

^az MOUNT SINAI HOSPITAL   (Canada)

^ba GRADUATE HOSPITAL   (United States)

^bb EMORY UNIVERSITY HOSPITAL   (United States)

^bc St Joseph Hospital   (United States)

^bd HEALTH SCIENCES CENTRE   (Canada)

^be ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^bf QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^bg ST BONIFACE GENERAL HOSPITAL   (Canada)

^bh FOOTHILLS HOSPITAL   (Canada)

^bi BAPTIST MEMORIAL HOSPITAL   (United States)

^bj RUSH UNIVERSITY MEDICAL CENTER   (United States)

^bk LONDON HEALTH SCIENCES CENTRE   (Canada)

^bl ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^bm KEESLER MEDICAL CENTER   (United States)

^bn UNIVERSITY OF MANITOBA   (Canada)

^bo OUR LADY OF LOURDES MEDICAL CENTER   (United States)

^bp UNIVERSITY HEALTH NETWORK   (Canada)

^bq BAYLOR COLLEGE OF MEDICINE   (United States)

^br SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^bs ST PAUL S HOSPITAL   (Canada)

^bt VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^bu MONTREAL HEART INSTITUTE   (Canada)

^bv Northern Californian Medical Association   (United States)

^bw UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^bx Watson Clinic   (United States)

^by WESTERN PENNSYLVANIA HOSPITAL   (United States)

^bz Lancaster Heart Foundation   (United States)

^ca MidWest Cardiology Research Foundation   (United States)

^cb IOWA HEART CENTER   (United States)

^cc UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^cd ORLANDO REGIONAL MEDICAL CENTER   (United States)

^ce DURHAM VA MEDICAL CENTER   (United States)

^cf Milwaukee Heart and Vascular Clinic   (United States)

^cg CHRIST HOSPITAL   (United States)

^ch Western Montana Clinic   (United States)

^ci EAST TEXAS MEDICAL CENTER   (United States)

^cj Prairie Cardiovascular Consultants Ltd   (United States)

^ck Latter Day Saints Hospital   (United States)

^cl ST MICHAEL'S HOSPITAL   (Canada)

^cm CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; HEPARIN; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; EMERGENCY TREATMENT; ERYTHROCYTE TRANSFUSION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND LOOK SURGERY; SURGICAL MORTALITY; THROMBOCYTE TRANSFUSION;

EID: 0033836321     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/S0003-4975(00)01343-6     Document Type: Article

References (28)

1. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
3. Platelet glycoprotein IIb/IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization
4. Randomised placebo-controlled and balloon-angioplasty- controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
5. A randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
6. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
7. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
8. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery
9. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab
10. Prophylactic platelet transfusion in abciximabtreated patients requiring emergency coronary bypass surgery
11. Bleeding during thrombolytic therapy for acute myocardial infarction: Mechanisms and management
12. Practice strategies for elective red blood cell transfusion
13. Thrombolysis in myocardial infarction (TIMI) trial. Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
14. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy
15. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
16. Failed elective percutaneous transluminal coronary angioplasty requiring coronary artery bypass surgery. In-hospital and late clinical outcome at 5 years
17. Disrupted coronary artery caused by angioplasty: Supportive and surgical considerations
18. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Iimplications forinhibition of the internal pool of GPIIb/IIIa receptors
19. Reversal of the antiplatelet effects of chimeric 7E3 Fab treatment by platelet transfusion in cynomolgus monkeys
20. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: Increased costs and platelet transfusion requirements after the use of abciximab
21. Surgical implications of platelet glycoprotein IIb-IIIa inhibition
22. Determinants of red cell, plasma, and cryoprecipitate transfusions during coronary artery bypass graft surgery: The Collaborative Hospital Transfusion Study
23. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
24. Intracardiac thrombus: A risk of incomplete anticoagulation for cardiac operations
25. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
26. Inhibition of platelet adhesion during cardiopulmonary bypass reduces postoperative bleeding
27. Integrilin prevents prolonged bleeding times after cardiopulmonary bypass
28. DDAVP reduces blood loss and transfusion in cardiac surgical patients with impaired platelet function identified using a point-of-care test: A double-blind, placebo controlled trial